Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17070985 | 0.86 | GRIN2B (0.40) | GRIN2BGRIN2C | |
| SCHEMBL22213480 | 0.85 | GRIN2B (0.38) | GRIN2BGRIN2C | |
| SCHEMBL17030274 | 0.84 | GRIN2B (0.41) | GRIN2BGRIN2C | |
| SCHEMBL16646195 | 0.84 | GRIN2B (0.41) | GRIN2BGRIN2C | |
| SCHEMBL12047518 | 0.84 | CTSL (0.41) | — | |
| SCHEMBL12028815 | 0.83 | — | — | |
| SCHEMBL7933725 | 0.83 | CTSL (0.46) | RAB9A | |
| SCHEMBL7932040 | 0.83 | CTSL (0.46) | RAB9A | |
| SCHEMBL12028816 | 0.82 | SLC15A1 (0.39) | — | |
| SCHEMBL20126634 | 0.78 | MEN1 (0.44) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049845-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, OR OTHER DISORDERS | INNOVIVA TRC HOLDINGS LLC | 2017-02-23 | — | — | US | disclosed |
| US-20170049845-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, OR OTHER DISORDERS | INNOVIVA TRC HOLDINGS LLC | 2017-02-23 | — | — | US | disclosed |
| US-9512133-B2 | NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150336969-A1 | NMDA Receptor Modulators and Uses Thereof | NAUREX, INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150253305-A1 | METHODS OF IDENTIFYING COMPOUNDS FOR TREATING DEPRESSION AND OTHER RELATED DISEASES | NORTHWESTERN UNIVERSITY | 2015-09-10 | — | — | US | disclosed |
| US-20150105364-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
| US-20110306586-A1 | NMDA Receptor Modulators and Uses Thereof | NAUREX, INC. | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049845-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, OR OTHER DISORDERS | GRIN2A, GRIN3A, GRIN1 | HTT 29/4885NPC1 1273/4885RAB9A 2278/4885 |
| US-20150336969-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | HTT 956/4885NPC1 1109/4885RAB9A 2386/4885 |
| US-20150105364-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | HTT 956/4885NPC1 1109/4885RAB9A 2386/4885 |
| US-20110306586-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | HTT 956/4885NPC1 1109/4885RAB9A 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.